Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas

Area of Science:

• Neuro-oncology
• Epigenetics
• Molecular Biology

Background:

• High-grade gliomas with H3.3G34R/V mutations have a dismal prognosis and are resistant to current therapies.
• These mutations reprogram epigenetic modifications, suggesting a need for epigenetic-based therapeutic strategies.

Purpose of the Study:

• To define therapeutic vulnerabilities in H3.3G34R/V gliomas using a comprehensive epigenetic approach.
• To investigate the role of the leukemia inhibitory factor (LIF) and signal transducer and activator of transcription 3 (STAT3) pathway in H3.3G34R/V glioma pathogenesis.

Main Methods:

• ChIP sequencing and ChromHMM computational analysis to identify epigenetic alterations.
• Immunohistochemistry and single-cell RNA sequencing to assess STAT3 expression in patient tumors.
• In vitro and in vivo preclinical studies using the STAT3 inhibitor WP1066.

Main Results:

• Epigenetic alterations, including activating histone modifications and DNA hypomethylation, were identified.
• Redistribution of H3K27me3 at the LIF locus led to increased LIF secretion, activating STAT3 signaling.
• STAT3 inhibition with WP1066 demonstrated tumor cell toxicity in vitro and tumor suppression in preclinical models.

Conclusions:

• The LIF/STAT3 pathway is a key, epigenetically driven vulnerability in H3.3G34R/V gliomas.
• Targeting the LIF/STAT3 pathway with inhibitors like WP1066 offers a potential therapeutic strategy for these aggressive brain tumors.
• Findings support the development of targeted, combination therapies for H3.3G34R/V gliomas.